Find uplifting stories about heroes, innovations, and solutions
9 results for "hunter syndrome"
Rory Jaskulski received a newly approved treatment for rare Hunter syndrome just three weeks after FDA approval, transforming his family's outlook from planning a funeral to imagining his future. The New Berlin boy is among the first patients to access a medication the community waited nearly 20 years to see approved.
After 20 years without new treatments, the FDA approved Avlayah, the first therapy designed to treat both physical and neurological symptoms of Hunter syndrome. The breakthrough offers hope to families battling this rare disease that causes progressive organ damage and early death.
After 20 years, the FDA approved the first treatment for Hunter syndrome that can prevent brain damage in children. For families watching their kids lose the ability to speak and walk, it's a breakthrough they feared would never come.
Children with Hunter syndrome now have access to the first treatment that reaches the brain, addressing complications that existing therapies couldn't touch. The FDA approval opens doors for treating dozens of other neurological conditions.
Families dealing with Hunter syndrome just gained a powerful new treatment option after the FDA granted accelerated approval to Denali Therapeutics' groundbreaking drug. The decision marks a turning point for rare disease patients after a year of tougher regulatory outcomes.
Families affected by Hunter syndrome now have hope as the FDA approves Avlayah, the first treatment designed to replace a missing enzyme that causes dangerous sugar buildup in the brain. This breakthrough marks a major victory for patients with this rare genetic disease.
The FDA just approved Denali Therapeutics' new medicine for Hunter syndrome, bringing fresh hope to families affected by this rare genetic disease. The approval comes as a welcome surprise after the agency recently toughened its standards for rare disease treatments.
Children with Hunter syndrome just got their first new treatment option in nearly two decades. The FDA approved AVLAYAH, a breakthrough therapy from Denali Therapeutics that offers fresh hope to families facing this rare genetic disease.
Children with a rare genetic disorder are developing normally thanks to an enzyme therapy crossing the blood-brain barrier. The FDA could approve the treatment this spring, offering hope to families worldwide.